INT202196

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 2006
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 3.87
Pain Relevance 0.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Erbb2) plasma membrane (Erbb2) nucleus (Erbb2)
kinase activity (Erbb2) cytoplasm (Erbb2)
Anatomy Link Frequency
CNS 1
Erbb2 (Mus musculus)
Pain Link Frequency Relevance Heat
Central nervous system 160 96.56 Very High Very High Very High
Spinal cord 4 5.00 Very Low Very Low Very Low
agonist 4 5.00 Very Low Very Low Very Low
palliative 2 5.00 Very Low Very Low Very Low
intrathecal 2 5.00 Very Low Very Low Very Low
Pain 1 5.00 Very Low Very Low Very Low
headache 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 112 99.84 Very High Very High Very High
Disease 47 99.26 Very High Very High Very High
Recurrence 81 96.40 Very High Very High Very High
Cancer 79 91.20 High High
Bone Cancer 2 86.00 High High
Metastasis 104 85.88 High High
Advanced Or Metastatic Breast Cancer 24 81.48 Quite High
Disease Progression 14 80.52 Quite High
Solid Tumor 28 78.28 Quite High
Hyperplasia 1 72.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Two main methods exist for the determination of HER2 gene amplification and protein expression in breast cancer specimens, fluorescence in situ hybridisation or FISH (direct or indirect) and IHC.
Transcription (expression) of HER2 gene associated with breast cancer
1) Confidence 0.69 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 1.10 Pain Relevance 0
Multivariate analysis revealed that the stage of disease (odds ratio, 0.23; 95% confidence interval, 0.007–0.23; P = 0.0001), the HER2/neu status (odds ratio, 29.4; 95% confidence interval, 7.51–101.21; P = 0.0001) and the presence of CK-19 mRNA-positive CTCs (odds ratio, 8.31; 95% confidence interval, 3.97–12.84; P = 0.001) were independent predictive factors for CNS relapse.


Transcription (presence) of HER2/neu in CNS associated with central nervous system, disease and recurrence
2) Confidence 0.53 Published 2006 Journal Breast Cancer Res Section Abstract Doc Link PMC1779464 Disease Relevance 1.52 Pain Relevance 0.23
Table 5 demonstrates that the stage of disease (odds ratio, 0.23; P < 0.0001), the detection of CK-19 mRNA-positive CTCs (odds ratio, 8.31; P = 0.001) and the HER2/neu status (odds ratio, 29.41; P < 0.0001) emerged as independent predictive factors for CNS relapse.
Transcription (detection) of HER2/neu associated with central nervous system, disease and recurrence
3) Confidence 0.53 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779464 Disease Relevance 1.26 Pain Relevance 0.28

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox